Sorafenib Increases Survival In Patients With Late-Stage Liver Cancer
The oral multikinase inhibitor inhibitor sorafenib (Nexavar) significantly improves survival compared to placebo in patients with advanced hepatocellular carcinoma, according to phase III results reported at the 14th European Cancer Conference (ECCO).
